|
|
|
|
||
|
||
|
Vol. 18, Nos. 1-49, pp. 1-1676 Jan. 8 - Dec. 24, 2009 A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
ZOLADEX
– Average wholesale price inflation of prostrate cancer treatment
– – Class action settlement approved, funds may be used to benefit class members indirectly (1st Cir.), 1550
– – Mass. deceptive business practices claims, $12.9M judgment against AstraZeneca affirmed (1st Cir.), 1289
– Conn. attorney general announces settlement of unapproved uses suit (E.D.N.Y.), In Brief, 1298
– Eli Lilly agrees to pay $1.4B criminal fine to settle allegations of promoting off-label use (E.D. Pa.), 127 – Miss., most of state's off-label marketing and failure to warn claims dismissed (E.D.N.Y.), 1593 – S.C., attorney general settles suit to recover cost of treating side effects (S.C. Cir. Ct.), In Brief, 1436 – Utah, Lilly agrees to pay to settle off-label marketing suit (Utah Dist. Ct.), 1553 Contact the Webmaster at webmaster@bna.com Copyright © The Bureau of National Affairs, Inc. All Rights Reserved. |
